VistaGen Receives Nasdaq Notice on Minimum Bid Compliance

An update from VistaGen Therapeutics ( (VTGN) ) is now available.

On February 3, 2026, Vistagen Therapeutics, Inc. received a notice from Nasdaq that the company’s common stock had closed below the required minimum bid price of $1.00 per share for 30 consecutive business days, putting it out of compliance with Nasdaq’s continued listing standards. While the letter has no immediate impact on the stock’s current listing, Vistagen now has until August 3, 2026 to restore its share price to at least $1.00 for 10 consecutive business days, with the possibility of an additional 180-day compliance period if it meets other listing criteria, a development that underscores ongoing pressure on the company’s share price and introduces potential delisting risk for investors if compliance is not regained.

The most recent analyst rating on (VTGN) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.

Spark’s Take on VTGN Stock

According to Spark, TipRanks’ AI Analyst, VTGN is a Neutral.

The score is held down primarily by very weak financial performance (minimal revenue scale, large losses, and significant cash burn) and bearish technical signals (price well below key moving averages with negative MACD). The latest earnings call provides partial support via stated cash resources and multiple clinical milestones, but valuation metrics are not meaningfully supportive due to losses and no dividend yield.

To see Spark’s full report on VTGN stock, click here.

More about VistaGen Therapeutics

Vistagen Therapeutics, Inc. is a biopharmaceutical company whose common stock is listed on the Nasdaq Capital Market, giving it access to public equity markets to fund its drug development and related operations.

Average Trading Volume: 2,750,148

Technical Sentiment Signal: Sell

Current Market Cap: $20.78M

See more insights into VTGN stock on TipRanks’ Stock Analysis page.